window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Gene Editing

  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema

    Intellia Therapeutics has reported positive Phase 3 results for lonvoguran [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development

    Scribe Therapeutics secures milestone $1.5BN collaboration with Eli Lilly for in vivo CRISPR program

    Scribe Therapeutics has achieved a second success milestone in its [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    MaxCyte signs platform licence with Moonlight Bio to advance T cell therapies for solid tumours

    MaxCyte has entered a strategic platform licence with US biotech [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    Chiesi and Arbor partner on rare disease gene editing programmes targeting PH1 and other liver disorders

    Chiesi Group has entered into an exclusive global partnership with [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Opinion & Events

    Anocca raises SEK 440M to advance TCR-T cell therapies into clinical development

    Swedish clinical-stage biotech Anocca AB has secured approximately SEK 440 [...]

    May 5, 2026
  • Advanced Therapies,Therapeutic Areas

    Broken String renews NIST gene editing safety push with INDUCE-seq technology

    Broken String Biosciences has reaffirmed its commitment to supporting the [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Broken String and BioLizard partner on AI tool to improve gene editing safety

    Eurostars-3 grant supports development of SafeGuide to reduce time and [...]

    May 5, 2026
  • Advanced Therapies,Manufacturing & Supply Chain

    MaxCyte and Ori Biotech integrate platforms to improve cell therapy manufacturing

    CD19 CAR CRISPR T cell workflow used to demonstrate shortened [...]

    May 5, 2026
  • Advanced Therapies

    Cellistic unveils Echo-NK platform to scale up iPSC-based cell therapies

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Remepy and Merck KGaA partner on hybrid drug programmes
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • RxLogix launches AI pharmacovigilance platform for adverse event monitoring
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development
  • Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema
    Categories: Advanced Therapies, Clinical & Regulatory, Drug Discovery & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top